ZYME
USDZymeworks Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$18.390
Haut
$18.770
Bas
$18.000
Volume
0.08M
Fondamentaux de l'Entreprise
Capitalisation Boursière
1.4B
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.66M
Bourse
NMS
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.